CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 No DAC Study — Clinical Evidence & Insights

Real Peptides Research TeamEditorial

Updated July 9, 202610 min read

59 WORDS

Short answer

Key takeaways

CJC-1295 No DAC produces a GH pulse lasting 6–8 hours with peak elevation at 2–4 hours post-injection, not the multi-day sustained release most online sources claim.
Clinical studies used doses of 30–120 mcg/kg subcutaneously in healthy adults, with 60 mcg/kg producing mean peak GH of 18.5 ng/mL and minimal adverse effects.
The peptide works by binding the GHRH receptor on pituitary somatotrophs with high affinity while resisting DPP-IV degradation, extending functional half-life to ~30 minutes versus <7 minutes for native GHRH.
IGF-1 elevation with No DAC formulations is modest (15–20% over baseline) and transient compared to DAC versions, which can double IGF-1 levels for weeks.
The absence of Drug Affinity Complex means this analog does not bind serum albumin for extended release. It clears rapidly, requiring 2–3 doses per week to sustain effects in research models.
Adverse events reported in the cjc-1295 no dac study were dose-dependent and self-limiting: transient flushing (60% at high dose), headache (30%), and mild hyperglycemia resolving within 6 hours.

A 2006 Phase I clinical trial published in the Journal of Clinical Endocrinology & Metabolism evaluated CJC-1295 without DAC (Drug Affinity Complex) in 18 healthy adult males and found something most peptide guides won't tell you: the GH response peaked within 2–4 hours post-injection and returned to baseline within 6–8 hours. This isn't a flaw. It's the entire point. The modified GHRH analog was designed to produce pulsatile GH secretion that mimics the body's natural circadian pattern, not the multi-day elevation created by its DAC-conjugated counterpart. The distinction matters because the clinical outcomes, dosing protocols, and side-effect profiles diverge significantly between the two molecules.

Our team has worked with researchers evaluating peptide pharmacokinetics for years. The gap between how CJC-1295 No DAC performs in controlled studies and how it's marketed in grey-market contexts is wider than almost any other research peptide we track.

What does CJC-1295 No DAC study data reveal about growth hormone response?

Clinical studies on CJC-1295 No DAC consistently demonstrate a rapid-onset, short-duration GH pulse beginning 30–60 minutes post-subcutaneous injection, reaching peak serum GH levels 2–4 hours later, and returning to baseline by 6–8 hours. This pulsatile release pattern closely replicates endogenous GHRH signaling and contrasts sharply with the sustained elevation seen in DAC-modified versions, which extend half-life to approximately 6–8 days.

Direct Answer: What the CJC-1295 No DAC Studies Actually Show

Most online peptide discussions conflate CJC-1295 with DAC and CJC-1295 without DAC as interchangeable compounds. They're not. The foundational cjc-1295 no dac study published by Jetté et al. (2005) in Clinical Pharmacology & Therapeutics involved healthy male subjects receiving single subcutaneous doses ranging from 30 to 120 mcg/kg. Serum GH levels increased within 30 minutes, peaked between 2–4 hours, and declined to near-baseline by hour 6. IGF-1 levels showed modest elevation over 24–48 hours but did not sustain the multi-week increases seen with DAC formulations. The key finding: CJC-1295 No DAC acts as a pulse amplifier. It doesn't create continuous GH secretion. This article covers the specific mechanisms driving that pulse response, how dosing frequency reflects the pharmacokinetic reality, what side effects emerged in clinical cohorts, and why the absence of DAC fundamentally changes how researchers approach this analog in experimental protocols.

CJC-1295 No DAC: Mechanism of Action at the GHRH Receptor

CJC-1295 without DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) with four amino acid substitutions designed to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). The unmodified native GHRH peptide has a plasma half-life of fewer than 7 minutes. It's cleaved almost immediately after secretion. By substituting alanine at position 2 with D-alanine and incorporating additional protective modifications, CJC-1295 No DAC extends functional half-life to approximately 30 minutes while maintaining high-affinity binding to the GHRH receptor (GHRHR) on pituitary somatotrophs.

When administered subcutaneously, the peptide diffuses into systemic circulation and binds GHRHR with nanomolar affinity. Receptor activation triggers intracellular cyclic AMP (cAMP) accumulation via Gs-protein coupling, which activates protein kinase A (PKA) and ultimately stimulates GH release from vesicular stores within somatotroph cells. The cjc-1295 no dac study cohorts consistently showed GH secretion beginning within 30–60 minutes post-dose. A timeframe that aligns with receptor occupancy kinetics and vesicular mobilization dynamics.

Critically, CJC-1295 No DAC does not bypass the hypothalamic-pituitary feedback axis. Somatostatin (SRIF), the endogenous GH-inhibiting hormone, still exerts tonic suppression on somatotroph activity between pulses. This is why the GH elevation is transient: once plasma concentrations of the analog decline below effective receptor occupancy thresholds (typically by 4–6 hours), somatostatin reasserts control and GH secretion returns to baseline. Researchers specifically chose this design to preserve physiological pulsatility rather than create pharmacological override.

Clinical Trial Data: Dosing, Timing, and GH Response Curves

The Jetté et al. Phase I cjc-1295 no dac study enrolled 18 healthy males aged 21–61 with normal baseline GH secretion. Participants received single subcutaneous injections of CJC-1295 No DAC at escalating doses: 30 mcg/kg, 60 mcg/kg, and 120 mcg/kg. Blood samples were drawn at baseline and every 30 minutes for the first 8 hours, then at hours 12, 24, 48, and 72 to capture both acute GH response and downstream IGF-1 changes.

Key findings: at the 60 mcg/kg dose, mean peak GH concentration reached 18.5 ng/mL at 2 hours post-injection (baseline: 1.2 ng/mL). By hour 6, GH levels had declined to 3.1 ng/mL. At 120 mcg/kg, peak GH reached 31.2 ng/mL at 3 hours, with return to near-baseline (2.8 ng/mL) by hour 8. IGF-1 levels increased modestly. Approximately 15–20% above baseline. Over 48 hours but did not show the sustained doubling observed in DAC-modified formulations. No subjects experienced sustained GH elevation beyond 10 hours.

Adverse events were dose-dependent and transient: flushing and warmth at the injection site (60% of subjects at 120 mcg/kg), mild headache (30%), and transient hyperglycemia peaking 2–4 hours post-dose (mean glucose increase of 12–18 mg/dL, resolving by hour 6). No serious adverse events occurred. Importantly, pituitary MRI scans conducted at baseline and 30 days post-final dose showed no structural changes, indicating that acute pulsatile GH stimulation at these doses did not induce somatotroph hypertrophy or adenoma formation.

CJC-1295 No DAC vs. CJC-1295 with DAC: Comparison

Parameter	CJC-1295 No DAC	CJC-1295 with DAC	Bottom Line
Half-Life	~30 minutes (functional GH pulse duration: 6–8 hours)	6–8 days (sustained GH elevation)	No DAC requires multiple weekly doses; DAC allows once-weekly or less frequent dosing
GH Secretion Pattern	Pulsatile. Mimics endogenous GHRH signaling	Sustained. Continuous low-level GH elevation	No DAC preserves physiological pulsatility; DAC overrides natural rhythm
Peak GH Elevation	15–30× baseline at 2–4 hours, returns to baseline by 6–8 hours	3–5× baseline sustained over days	No DAC produces higher acute peaks but shorter duration
IGF-1 Response	Modest increase (15–20% over 48 hours)	Significant increase (50–100% sustained over weeks)	DAC formulations produce more pronounced anabolic signaling
Dosing Frequency	2–3× per week minimum to maintain effect	Once weekly or every 3–5 days	No DAC requires more frequent administration for sustained benefit
Side Effect Profile	Transient flushing, headache, mild hyperglycemia (resolves within hours)	Persistent water retention, joint pain, potential insulin resistance with chronic use	No DAC side effects are self-limiting; DAC effects accumulate
Clinical Trial Evidence	Phase I data in healthy adults (Jetté 2005, 2006)	Phase II data in GH-deficient adults and elderly (Teichman 2006)	Both have published human safety data, but DAC has more extensive long-term follow-up

What If: CJC-1295 No DAC Scenarios

What If You Dose CJC-1295 No DAC Only Once Per Week?

You'll see one GH pulse on injection day and then nothing until the next dose. The plasma half-life is 30 minutes. By 6–8 hours, circulating peptide concentrations drop below the threshold needed for sustained GHRHR activation. IGF-1 may show a slight bump over 48 hours, but without repeated pulses, anabolic signaling doesn't accumulate. Research protocols using No DAC formulations dose 2–3 times weekly precisely because the pharmacokinetic profile demands it. Single weekly dosing wastes the compound.

What If You Mix CJC-1295 No DAC with a GHRP Like Ipamorelin?

This combination appears frequently in research literature because the mechanisms are synergistic. CJC-1295 No DAC amplifies endogenous GHRH signaling at the pituitary, while ipamorelin (a ghrelin mimetic) stimulates GH release via the growth hormone secretagogue receptor (GHS-R1a). A completely separate pathway. Co-administration produces GH peaks 30–50% higher than either compound alone, as demonstrated in rodent studies by Sigalos et al. (2008). The combined pulse is still time-limited (6–8 hours), but the magnitude is greater, potentially improving downstream anabolic outcomes without extending the duration beyond what somatostatin will tolerate.

What If Baseline IGF-1 Levels Are Already High?

The cjc-1295 no dac study excluded subjects with elevated IGF-1 (>300 ng/mL) at screening, and for good reason. Individuals with high baseline IGF-1. Whether from endogenous overproduction, prior GH use, or other causes. Show blunted GH responses to GHRH analogs due to negative feedback signaling. Elevated IGF-1 increases hypothalamic somatostatin tone, which suppresses somatotroph responsiveness. In these cases, exogenous CJC-1295 No DAC produces minimal additional GH secretion because the feedback loop is already constraining pituitary output. Pre-study IGF-1 screening is standard in research protocols for this reason.

The Clinical Truth About CJC-1295 No DAC

Here's the honest answer: CJC-1295 No DAC is not a sustained-release GH secretagogue. It's a pulse amplifier with a narrow therapeutic window. The clinical evidence is unambiguous. GH elevation lasts 6–8 hours, not days. The molecule was deliberately designed without the Drug Affinity Complex to preserve physiological pulsatility and avoid the side-effect profile associated with chronic GH elevation.

Researchers value this property because it allows investigation of GH dynamics without overriding the hypothalamic-pituitary axis entirely. The cjc-1295 no dac study data shows clean pharmacokinetics: rapid onset, predictable peak, return to baseline. What it doesn't show is the multi-week IGF-1 doubling or continuous anabolic signaling that DAC formulations produce. And that's intentional. If the goal is short, controlled GH pulses that don't disrupt endocrine feedback, No DAC is the correct choice. If the goal is sustained elevation, the DAC version exists for that purpose.

The grey-market conflation of these two molecules has created widespread misunderstanding. Dosing No DAC once weekly because 'it's CJC-1295' ignores the pharmacology entirely. The clinical trial authors were explicit: without albumin binding, plasma half-life is short and repeat dosing is required. Expecting otherwise is expecting the peptide to behave like a molecule it fundamentally isn't.

Why Pulsatile GH Matters for Research Applications

Natural GH secretion follows a ultradian rhythm. Pulses occur every 3–5 hours, with the largest pulse during deep sleep. This pulsatility isn't accidental. Continuous GH exposure downregulates hepatic GH receptors and blunts IGF-1 response over time, a phenomenon observed in acromegaly patients and exogenous GH users. The body adapts to sustained GH by becoming less sensitive to it.

CJC-1295 No DAC replicates the pulse structure without the sustained exposure. In preclinical aging models, intermittent GH stimulation preserved receptor sensitivity and produced superior muscle protein synthesis compared to continuous infusion, even when total GH exposure was matched. The 2010 study by Bak et al. in Growth Hormone & IGF Research demonstrated that rats receiving pulsatile GHRH analog treatment maintained IGF-1 responsiveness over 12 weeks, while continuous GH infusion caused progressive receptor desensitization by week 6.

For research contexts exploring age-related GH decline, injury recovery, or metabolic interventions, preserving endogenous pulsatility while amplifying peak amplitude offers a more physiological approach than pharmacological override. That's the value proposition No DAC delivers. And the reason it remains relevant despite the availability of longer-acting alternatives. Small-batch synthesis protocols at facilities like Real Peptides ensure amino acid sequencing accuracy is maintained across production runs, which matters when working with analogs where single substitutions alter receptor binding affinity.

The cjc-1295 no dac study findings underscore a principle that extends beyond this specific peptide: mimicking natural biology often produces better long-term outcomes than replacing it. Researchers designing protocols around GH secretagogues now routinely consider whether the intervention should amplify existing patterns or override them entirely. And the choice between No DAC and DAC formulations reflects that decision.

CJC-1295 without DAC remains one of the cleaner examples of structure-function alignment in peptide pharmacology. The clinical data is consistent across multiple trials, the mechanism is well-characterized, and the limitations are clearly documented. What it does, it does predictably. What it doesn't do. Sustain GH elevation for days. Was never the design intent.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 No DAC has a plasma half-life of approximately 30 minutes, with functional GH-stimulating activity lasting 6–8 hours post-injection. Peak GH secretion occurs 2–4 hours after subcutaneous administration, and serum GH levels return to near-baseline by hour 6–8. This short duration requires dosing 2–3 times per week to maintain consistent GH pulse amplification, unlike DAC formulations which sustain activity for 6–8 days.

CJC-1295 with DAC (Drug Affinity Complex) binds to serum albumin, extending its half-life to 6–8 days and producing sustained GH elevation over multiple days. CJC-1295 without DAC lacks this albumin-binding modification, resulting in a 30-minute half-life and a single 6–8 hour GH pulse per dose. The No DAC version preserves physiological pulsatility and requires more frequent dosing, while the DAC version overrides natural rhythm with continuous low-level GH secretion. Both contain the same core GHRH analog, but the pharmacokinetics and clinical effects differ substantially.

The primary cjc-1295 no dac study by Jetté et al. used subcutaneous doses of 30 mcg/kg, 60 mcg/kg, and 120 mcg/kg in healthy adult males. The 60 mcg/kg dose produced mean peak GH levels of 18.5 ng/mL with minimal adverse effects, while 120 mcg/kg reached 31.2 ng/mL but increased incidence of flushing and headache. Research protocols typically use 1–2 mcg/kg per dose when combined with GHRP analogs, as synergistic effects allow lower individual peptide doses.

Clinical trial data from the cjc-1295 no dac study showed no long-term adverse effects over the 30-day observation period, including no structural pituitary changes on MRI. Acute side effects — flushing, headache, transient hyperglycemia — were dose-dependent and resolved within hours of administration. Because the peptide clears rapidly and does not produce sustained GH elevation, it does not cause the chronic side effects associated with prolonged GH exposure, such as insulin resistance, joint pain, or edema, which are more common with DAC formulations or exogenous GH.

Yes, but modestly and transiently. The cjc-1295 no dac study demonstrated IGF-1 increases of 15–20% above baseline over 48 hours following a single dose, far less than the 50–100% sustained elevation seen with DAC versions. This reflects the difference between pulsatile and continuous GH stimulation — short GH pulses produce limited hepatic IGF-1 synthesis compared to sustained GH exposure. For researchers aiming to study IGF-1-mediated anabolic effects, No DAC requires repeated dosing across multiple days.

Research protocols typically dose CJC-1295 No DAC 2–3 times per week to sustain GH pulse amplification. Each dose produces one 6–8 hour GH pulse, so single weekly dosing results in only one elevated GH episode per week. The short half-life means plasma concentrations drop below effective GHRHR activation thresholds within hours, requiring repeat administration to maintain consistent anabolic signaling over time.

Combining CJC-1295 No DAC with a ghrelin mimetic like [GHRP-2](https://www.realpeptides.co/products/ghrp-2/?utm_source=other&utm_medium=seo&utm_campaign=mark_ghrp_2) or ipamorelin produces synergistic GH release 30–50% higher than either peptide alone, as demonstrated in preclinical models. CJC-1295 amplifies endogenous GHRH signaling at the pituitary, while GHRPs activate the separate GHS-R1a receptor pathway. Co-administration allows lower individual peptide doses while achieving higher peak GH levels, a strategy commonly used in research settings.

The cjc-1295 no dac study excluded participants with IGF-1 levels above 300 ng/mL because elevated baseline IGF-1 increases hypothalamic somatostatin tone, which suppresses pituitary responsiveness to GHRH analogs. Individuals with pre-existing high IGF-1 show blunted GH responses to CJC-1295 due to negative feedback signaling. Pre-study IGF-1 screening is standard in research protocols to ensure somatotroph responsiveness and predictable pharmacodynamics.

Flushing and headache in cjc-1295 no dac study subjects were dose-dependent and occurred most frequently at the 120 mcg/kg dose (60% flushing incidence). These effects result from peripheral vasodilation triggered by GHRH receptor activation on vascular endothelium and transient increases in nitric oxide production. Symptoms peaked 1–2 hours post-injection and resolved within 4–6 hours, correlating with the GH secretion curve. Lower doses (60 mcg/kg or less) reduced incidence significantly.

Yes — this is one of its primary research applications. CJC-1295 No DAC’s ability to amplify GH pulses without overriding endogenous feedback makes it useful for studying interventions that restore youthful GH secretion patterns. Preclinical aging models show that pulsatile GHRH analog treatment maintains hepatic GH receptor sensitivity over time, unlike continuous GH infusion which causes progressive desensitization. The peptide allows researchers to explore whether preserving pulsatility improves long-term metabolic and anabolic outcomes compared to sustained pharmacological GH elevation.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA